Results 141 to 150 of about 44,893 (265)

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, EarlyView.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

Rapid Transformation to Myeloid Blast Crisis in a Pediatric CML Patient Harboring a Complex t(7;9;22)(q11.23;q34;q11.2) Variant Translocation: A Case Report. [PDF]

EJHaem
Haidary AM, Noor S, Hussaini N, Amarkhail A, Ahmad M, Muhib I, Esmat E, Malakzai HA, Hakimi A, Haidari M, Ibrahimkhil AS, Saadaat R.   +11 more
europepmc   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies. [PDF]

BMC Cancer
Radwan SM, Mostafa D, Radwan RA, Elghobary HA, Elghamry WR, Kamal AM.   +5 more
europepmc   +1 more source

Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma

Histopathology, EarlyView.
New concepts, innovations and some issues have emerged since the adoption a decade ago of WHO/ISUP grading for CCRCC and PRCC. Continued use of the WHO/ISUP grading for CCRCC and PRCC has been upheld by newer studies, and practice guidance for some of the grading issues, where data are available, is provided.
Gladell P. Paner, Mahul. B. Amin, Jung Woo Kwon, Liang Cheng, Holger Moch   +4 more
wiley   +1 more source

The addition of CD38 monoclonal antibody to triplet regimens improves survival in newly diagnosed multiple myeloma with high-risk cytogenetics: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Hu B, Fang D, Jiang L, Li T, Chen K, Cao J, Wang J.   +6 more
europepmc   +1 more source

Hypereosinophilia of persistent/unknown cause: a bone marrow-based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing. [PDF]

Am J Clin Pathol
Eletrebi MM, Sanchez-Ramirez J, Abdalla A, Holman CJ.   +3 more
europepmc   +1 more source

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

Special Issue "Human Traits and Genomics: An Integrative Perspective". [PDF]

Int J Mol Sci
Saccone S, Larizza L, Malerba G.
europepmc   +1 more source